REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered Consisting Of One Nitrogen And Five Carbon Atoms > Polycyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos > Bicyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos > Quinolines (including Hydrogenated) Quinolines (including Hydrogenated)Quinolines (including Hydrogenated) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027184 - Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of ... 01/04/07 - 20070004773 - Amorphous salt of 4-(3-chiloro-4-(cycloproplylaminocarbonyl)aminophenoxy)-7-method-6-quinolinecarboxamide and process for preparing the same An amorphous form of a salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide. ... 12/07/06 - 20060276505 - Acylhydrazine p2x7 antagonists and uses thereof a pharmaceutically acceptable salt, ester, amide or prodrug thereof, wherein R3 and R4 are defined in the description. ... 11/16/06 - 20060258702 - Stabilization of hypoxia inducible factor (hif) alpha The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided. ... 11/02/06 - 20060247271 - Sulphonyl hydroxamic acid derivatives as inhibitors of s-cd23 wherein R is hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl; and R1 is bicyclyl or heterobicyclyl; are useful in the treatment and prophylaxis of conditions mediated by s-CD23. ... 09/21/06 - 20060211729 - Combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases Pharmaceutical compositions comprising an anticholinergic and at least one leukotriene inhibitor for treatment of respiratory diseases, including allergic rhinitis, bronchial asthma, COPD and common cold, and methods of treatment. ... 09/07/06 - 20060199840 - Chemical derivatives and their application as antitelomerase agent The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans. ... 08/31/06 - 20060194840 - Method for treating snoring and sleep apnea with leukotriene antagonists A method of treating snoring and/or sleep apnea comprising administering to a patient in need of such treatment a therapeutically effective amount of a leukotriene receptor antagonist. ... 08/31/06 - 20060194839 - Process for the preparation of montelukast (c) optional conversion of the salt A4 into the compound A3; (d) methylation of the salt A4 and/or of the compound A3 to yield Montelukast. ... 08/31/06 - 20060194838 - Polymorphic form of montelukast sodium The invention provides novel polymorphic form of montelukast sodium, as well as methods of using and pharmaceutical compositions containing saud novel form. Also provided are montelukast sodium: acetonitrile solvates, which are intermediates in the formation of crystalline montelukast sodium. ... 08/17/06 - 20060183771 - Novel combination of selective factor viia and/or factor xia inhibitors and selective plasma kallikrein inhibitors The present invention relates to a novel pharmaceutical combination for treating thromboembolic and/or inflammatory diseases, wherein the combination has: (a) a first therapeutic agent independently selected from the group consisting of a selective Factor VIIa inhibitor, a selective Factor XIa inhibitor, a combination of the selective Factor VIIa and XIa ... 07/27/06 - 20060167045 - Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist The present invention relates to the treatment of hypertension and type 2 diabetes, Metabolic Syndrome or a pre-diabetic state, by the administration of a therapeutically effective amount of a combination of a dual PPARα/γ agonist and an Angiotensin II type I receptor antagonist, including pharmaceutically acceptable salts and solvates of ... 07/20/06 - 20060160849 - Pharmaceutical compositions containing sulphonic acid derivatives A naphthalenesulfonic acid or quinolinesulfonic acid of formula (I), wherein A is N or a CR8 formula group, where R8 is H, OH, NR10R11, independently from one another, where R10 and R11 represent H or C1-C6 alkyl or a group of formula NH—CO—R12, where R12 is C1-C6 alkyl or C6-C10 ... 06/29/06 - 20060142335 - Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors The present invention relates to new substituted carbamic acid quinoline-6-yl esters of formulae 1 and 2 where R1=alkyl, aryl; R2=H, alkyl, aralkyl useful as acetylcholinesterase inhibitors, and which show potent antiacetylcholinesterase activity and have potential therapeutic use for prevention or cure of acetylcholinesterase related disorders including peripheral as well as ... 06/29/06 - 20060142334 - Tetrahydroquinoline derivatives The present invention relates to tetrahydroquinoline derivatives having gene formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are H or Me; R3 is H, hydroxy, (1-4C)alkoxy, (di)(1-4C)alkylamino(2-4C)alkoxy or (2-6)heterocycloakl(2-4C)alkoxy; R4 is H, OH, (1-4C)alkoxy or R7; R5 is H, OH, (1-4C)alkoxy or R7, with the proviso ... 06/08/06 - 20060122224 - Quinoline and quinoxaline compounds Quinoline and quinoxaline compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of ... 06/08/06 - 20060122223 - Substituted amino carboxylic acids which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative ... 06/08/06 - 20060122222 - Heterocycle substituted carboxylic acids which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative ... 06/08/06 - 20060122221 - Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis Compounds of formula (I): wherein A is a 5-membered heteroaryl ring are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38, such as rheumatoid arthritis. ... 05/18/06 - 20060106059 - Melanocortin receptor ligands W is a unit which preferable comprises D-(4-fluorophenyl)alanine, Y comprises at least one nitrogen heteroatom, and Z comprises an aromatic carbocyclic ring. Also disclosed are pharmaceutical compositions comprising the ligands of the invention as well as methods of treating diseases mediated through MC-3/MC-4 receptors. ... 05/18/06 - 20060106058 - Chemical compounds 3-carboxy quinoline derivatives, which are useful as YAK3 inhibitors are described herein. The described invention also includes methods of making such 3-carboxy quinoline derivatives as well as methods of using the same in the treatment of diseases mediated by inappropriate YAK3 activity. ... 05/04/06 - 20060094755 - Novel quinoline-based metal chelators as antiviral agents wherein A or B are independently —CR7R8, or —CH(R9)CH(R10). X is hydrogen, C1-C10 alkyl; —OH, or —NR11R12. R1 to R12 are various substituents selected to optimize the physicochemical and biological properties such as enzyme binding, tissue penetration, lipophilicity, toxicity, bioavailability, and pharmacokinetics of compounds of Formula 13. R1 to R12 ... 05/04/06 - 20060094754 - Quinolines as allosteric enhancers of the gabab receptors wherein R1 to R6 are as described herein, which compounds are active at the GABAB receptor and can be used for the preparation of medicaments useful in the treatment of CNS disorders comprising anxiety and depression. ... 04/27/06 - 20060089381 - Method of producing ethyl (3r, 5s, 6e)-7-[2 cyclopropyl-4-(fluorophenyl) quinoline-3-yl]-3, 5-dihydroxy-6-heptenoate A method of producing Ethyl (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinoline-3-yl]-3,5-dihydroxy-6-heptenoate by means of liquid chromatography using a packing material comprising a carrier and, carried thereon, a polysaccharide derivative, wherein a part or all of the hydrogen atoms of hydroxyl and amino groups of the polysaccharide derivative are substituted with one or more substituents, such ... 04/27/06 - 20060089380 - 8-hydroxy quinoline derivatives The present invention relates to a method for the treatment, amelioration and/or prophylaxis of a neurological condition, in particular neurodegenerative disorders which comprises the administration of an effective amount of a compound of formula (I): to a subject in need thereof. The present invention also relates to a compound of ... 04/13/06 - 20060079551 - Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors The present application is directed to a method of treating diseases of the central nervous system (CNS) comprising administering to a individual in need of treatment a therapeutically effective amount of an inhibitor of histone deacetylase. In particular embodiments, the CNS disease is a neurodegenerative disease. In further embodiments, the ... 04/13/06 - 20060079550 - Amino acid derivatives useful for the treatment of alzheimer's disease The present invention is a method of treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of known compounds of formula (I): wherein R1, R2, R3, R4, W and Cx are herein defined. ... 04/06/06 - 20060074104 - Use of clioquinol for the therapy of alzheimer's disease The invention relates to the identification of clioquinol as a pharmaceutically therapeutic agent for treatment of Alzheimer's disease and related pathological conditions. ... 03/02/06 - 20060046996 - Method for treating hyperlipidemia Provided is a method for treating hyperlipidemia or hypercholesterolemia, which comprises administering effective doses of ezetimibe and pitavastatin or a salt or lactone derivative thereof. ... 02/23/06 - 20060040981 - Use of phosphodiesterase-4 inhibitors as enhancers of cognition The present invention is directed to a method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of a phosphodiesterase-4 inhibitor. In particular, this invention is directed to a method of enhancing memory, learning, retention, recall, awareness and judgement in health subjects comprising administering a ... 02/16/06 - 20060035929 - Combination therapeutic compositions and methods of use Combination therapies of substituted quinolines and substituted diphenyl sulfones are disclosed. More specifically, compositions containing substituted quinolines and substituted diphenyl sulfones are disclosed. In addition, methods of using the compositions in the treatment of neurodegenerative disorders, including, inter alia, Alzheimer's dementia, HIV-1 associated dementia, and Creutzfeld-Jakob disease are also disclosed. ... 01/19/06 - 20060014787 - Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized ... 01/12/06 - 20060009487 - Heterocyclic derivatives for treatment of hyperlipidemia and related diseases The present invention provides compositions adapted to enhance reverse cholesterol transport in mammals. The compositions are suitable for oral delivery and useful in the treatment and/or prevention of hypercholesterolemia, atherosclerosis and associated cardiovascular diseases. ... 12/22/05 - 20050282855 - Susceptibility gene for myocardial infarction, stroke, and paod; methods of treatment Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in ... 12/15/05 - 20050277665 - Arylsulfones and uses related thereto Aryl sulfone compounds of formula I and II are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders: ... 12/08/05 - 20050272768 - Process for preparation of amorphous form of a drug Provided is a process for preparation of amorphous form of an active pharmaceutical ingredient. ... 11/24/05 - 20050261337 - Substituted quinoline derivatives The present invention relates to new substituted quinoline compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula: ... 11/24/05 - 20050261336 - Use of quinoline derivatives with anti-integrase effect and applications thereof The invention relates to the use of 8-hydroxyquinoline 7-carboxylic acid derivatives in order to produce integrase-inhibiting medicaments, capable of blocking viral replication in the stages preceding integration, and if appropriate at the level of this integration stage, these medicaments being usable for the treatment of retroviral pathologies, in particular for ... 11/17/05 - 20050256156 - Processes for preparing montelukast sodium The present invention provides processes for preparing montelukast. ... 11/03/05 - 20050245569 - Process for making montelukast and intermediates therefor is provided. ... 11/03/05 - 20050245568 - Process for making montelukast and intermediates therefor is provided. ... 10/13/05 - 20050228015 - Substituted heteroaryl- and phenylsulfamoyl compounds The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including ... 09/15/05 - 20050203128 - Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof and R2, R3, R4, R5, R6, Y, Z, X1 and X2 are as defined herein for Formula (IA) and Formula (IB), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated ... 09/08/05 - 20050197361 - Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors The invention relates to tetrahydroquinolinone derivatives as well as their pharmaceutially acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR antagonists and are therefore useful for the control and prevention of acute and/or chronic neurological ... 08/25/05 - 20050187245 - Stable amorphous forms of montelukast sodium An amorphous form of montelukast sodium and a montelukast sodium lactose co-precipitate, processes for producing same, pharmaceutical compositions containing same and methods of treatment utilizing same are disclosed. ... 08/25/05 - 20050187244 - Montelukast sodium polymorphs The present invention provides high crystallinity montelukast sodium, crystalline forms of montelukast sodium, and processes of preparing the same. ... 08/25/05 - 20050187243 - Montelukast free acid polymorphs The present invention relates to amorphous and polymorphic forms of montelukast free acid. ... 08/11/05 - 20050176762 - Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists A compound of formula (I) as detailed in the specification or a pharmaceutically acceptable salt or solvate thereof, a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds in medicine. ... 07/28/05 - 20050165052 - Substituted quinolines for the treatment of protozoa and retrovirus co-infections The invention relates to the use of quinolines having general formula (1), wherein R1 denotes H; alkyl C1-C15; alkenyl or alkynyl C2-C15; —CHO; heteroaryl; alkyl C1-C15 or alkenyl or alkynyl C2-C7 comprising at least one substituent selected from among O, halogen, —OH, —CHO, —COOH, aryloxycarbonyl, alkyloxycarbonyl C2-C8, alkenyloxycarbonyl C3-C9, nitrile, ... 07/21/05 - 20050159446 - Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof wherein substitutions at LG″, PG, A, G, R1 and R4 are set forth in the specification. ... 07/07/05 - 20050148627 - Benzopyran compounds for use in the treatment and prevention of inflammation related conditions Wherein Z, X, R1, R2, R3, and R4 are as described in the specification. ... 07/07/05 - 20050148626 - Novel thromodulin expression promoters It is intended to provide a novel pharmaceutical effect of HMG-CoA reductase inhibitors, in particular, (+)-(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid or its salt. Namely, TM expression promoters, more specifically speaking, antithrombotic drugs, preventive/remedies for sepsis, antiplatelet drugs and anticoagulants comprising as the active ingredient an HMG-CoA reductase inhibitor, in particular, (+)-(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic ... 06/16/05 - 20050131014 - Quinolines useful in treating cardiovascular disease that are useful in the treatment or inhibition of LXR mediated diseases. ... 06/16/05 - 20050131013 - Fungicide 5,7-Dibromo-8-(2-hydroxyethyl) quinoline, 5,7-dibromo-8-(2-methoxycarbonyloxyethyl) quinoline, fungicidal compositions containing these compounds and methods of treating plant diseases with these compounds. ... ### FreshPatents.com Support |